CURE
Global X S&P Biotech ETF
🇦🇺 ASX
🩺 HEALTH CARE
🇺🇸 UNITED STATES
👑 Overview
📈 Performance
📙 Holdings
💰 Distributions
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 0.47%
Annual Growth
5 years average annual growth
💰
0.07%
Annual distribution yield
Based on the most recent distribution
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
85
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.
📈 Performance
Price History
+4.35%
1M
1Y
All Time
Graph
Table
How could long term investing grow your wealth?*
Based on an initial investment of
$
and recurring investments every
for
$
Your wealth could grow to...
$62,238.23
after 5 years
$124,428.41
after 10 years
*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →📙 Top Holdings
Show more
Updated as of 28 October 2024
Industry Exposure
🩺 Health
100%
Country Exposure
🇺🇸 United States
100%
💰 Distributions
Payouts
💰 Annual Distribution Yield*
0.07%
💰 Annual Distribution Earnings Per $1,000 invested**
$0.65
💰 Most Recent Distribution Franked Percentage Estimate
0.00%
💰 Average Distribution Franked Percentage Estimate
0.00 %
💰 Distribution reinvestment
* Based on the most recent distribution
** Calculated by multiplying the most recent distribution yield by $1,000
Estimate your distribution
If you held
$
of CURE, your last distribution payment(s) would have been:
$ 6.51
on Fri Jul 15 2022
$ 908.32
on Thu Jul 15 2021
*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.
Distribution History
1Y
5Y
10Y
Graph
Table
Year
Yearly Distribution Earnings Per Share
Franking Estimate
2024
$0.00
0.00%
2023
$0.00
0.00%
2022
$0.00
0.00%
2021
$6.26
NaN%
2020
$6.76
NaN%
2019
$1.17
0.00%
2018
$0.00
0.00%
2017
$0.00
0.00%
2016
$0.00
0.00%
2015
$0.00
0.00%
💵 Costs
💼
0.45%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$51.12
💰 Price To Earnings Ratio
0.00
💰 Price To Book Ratio
5.03
💰 Leveraged
No
💰 Inverse
No
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in CURE
85
📊 Total Capital Earnings
$86K
🔃 Average investment frequency
33 weeks
💵 Average investment amount
$1,488
⏰ Last time a customer invested in CURE
5 days
CURE investor breakdown
💵 Income of investors
More than 200k
150k - 200k
8%
100k - 150k
23%
50k - 100k
43%
Less than 50k
18%
👶 Age of investors
18 - 25
26 - 34
44%
35 - 90
54%
🙋 Legal gender of investors
Female
46%
Male
54%
Pearlers who invest in CURE also invest in...
ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The ETF currently has 493.8m in AUM and 35 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).
🙌 Performance (5Yr p.a)
13.80%
📊 Share price
$83.40 AUD
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
🇦🇺 EX AUSTRALIA
🏭 INDUSTRIALS
ROBO.AX was created on 2017-09-13 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the ROBO.AX Global Robotics and Automation Index (the Index)
🙌 Performance (5Yr p.a)
4.32%
📊 Share price
$73.25 AUD
🇦🇺 EX AUSTRALIA
🤖 TECHNOLOGY
🏭 INDUSTRIALS
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.94%
📊 Share price
$101.26 AUD
🇦🇺 AUSTRALIA
💸 FINANCIALS
🧱 MATERIALS
⛳️ DIVERSIFIED
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.74%
📊 Share price
$66.59 AUD
🌏 GLOBAL
⛳️ DIVERSIFIED
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
18.98%
📊 Share price
$57.91 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
Want more shares? Try these...
Copper Search Ltd. is a mineral exploration and development company focused on the Gawler Craton Region of South Australia. The firm is engaged in targeting the copper-gold deposits within the Gawler Craton of South Australia. Its projects include the Peake Project, Billa Kalina Project, and North Titan Project. Its Peake project is in the NE Gawler Craton, prospective for copper (IOCG) deposits. The company has 100% ownership of the 5,560 square kilometers (km2) of the Peake Project. The project is prospective for iron-ore-copper-gold (IOCG) and iron-sulphide-copper-gold (ISCG) deposits. The firm has identified six potential IOCG drill targets from over 40 geophysical anomalies. Its tenements are held through its 100%-owned subsidiary, Copper Search Australia Pty Ltd. Its tenements include Curdimurka, Anna Creek, Allandale, Mt Arthur, Stuarts Creek, Callana, Ruby Hill, Spring Hill, Mt Denison, Blyth Creek, Dismal Plain, and Wantaman. Its drilling aims to identify IOCG target deposits with similar scale potential to Prominent Hill and Carrapateena.
📊 Share price
$0.04 AUD
⛏️ MINING
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).
🙌 Performance (5Yr p.a)
-11.25%
📊 Share price
$13.61 AUD
🧬 BIOTECHNOLOGY
Cullen Resources Ltd. is a mineral exploration company, which engages in the mineral exploration activities in Western Australia and Finland. The company is headquartered in Perth, Western Australia. The firm holds a multi-commodity portfolio including projects managed through a number of joint ventures with key partners (Rox, Fortescue, Capella and Lachlan Star), and a number of projects in its own right. The Company, through its wholly owned subsidiary Cullen Exploration Pty Ltd, holds exploration tenements and applications in prospective, mineralized regions in Western Australia, exploring for gold, base metals and rare-element pegmatites. Its key projects include Wongan Hills, North Tuckabianna, Barlee, Bromus South, Mt Eureka JV, Killaloe JV, and Finland. Wongan Hills Project is located 200 kilometers northeast of Perth in the Western Yilgarn province. The North Tuckabianna project lies along gold corridor stretching between Cue and Meekatharra.
🙌 Performance (5Yr p.a)
-10.28%
📊 Share price
$0.01 AUD
⛏️ MINING
Count Ltd. is a holding company, which engages in providing accounting and financial services. The company is headquartered in Sydney, New South Wales. The company went IPO on 2010-12-22. The firm provides a range of services, including accounting, financial advice and financial services. The firm subsidiary, Twomeys Group Pty Ltd, is specialized in accounting, tax, bookkeeping and advisory services. The Company, through Diverger Limited, offers technical support, tax training, separately managed accounts (SMAs) and information technology (IT) services. The firm has three segments. Core Firms comprises the provision of accounting, audit and assurance, taxation, financial planning services and business and corporate advisory services. Financial Advice comprises of financial advice services provided by Australian Financial Services License (AFSL) holders. Core Related comprises of services that support the activities of the Core Firms.
🙌 Performance (5Yr p.a)
-5.43%
📊 Share price
$0.77 AUD
💰 HIGH DIVIDEND
👔 PROFESSIONAL SERVICES